India's oncology market is shifting to precision medicine as CDSCO approvals expand immunotherapies, ADCs and targeted ...

Added white sugar and other refined carbohydrates can make up to 25% of the nutritional content of foods consumed on a daily ...

Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.

Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...

French pharma major Sanofi (Euronext: SAN) has received a Complete Response Letter (CRL) from the US regulator for ...

The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton’s tyrosine kinase (BTK) inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ...

After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining ...

Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, ...

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...